Back to results
US 2020/0046685 A1Published application
Combination therapy
AssigneeDimerix Bioscience Pty Ltd.
InventorsKevin D. G. Pfleger, Elizabeth McCall, James Williams
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeDimerix Bioscience Pty Ltd.
InventorsKevin D. G. Pfleger, Elizabeth McCall, James Williams
Estimating the term…
The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.
1-54. (canceled)
A method for the treatment or amelioration of a kidney disease associated with proteinuria in a patient being treated with at least one angiotensin 1 receptor (AT1R) blocker or a pharmaceutically acceptable salt thereof, the method comprising the step of further administering to the patient at least one chemokine receptor 2 (CCR2) inhibitor or a pharmaceutically acceptable salt thereof, wherein the at least one CCR2 inhibitor comprises a direct CCR2 antagonist;
The method of treatment or amelioration of claim 1, wherein the AT1R blocker:
The method of treatment or amelioration of claim 1, wherein the CCR2 inhibitor:
The method of treatment or amelioration of claim 1, wherein the kidney disease associated with proteinuria is selected from the group comprising:
The method of treatment or amelioration of claim 1, wherein the patient is being treated with about 5 mg to 1 g of the AT1R blocker or a pharmaceutically acceptable salt thereof, and is administered about 5 mg to 1 g of the CCR2 inhibitor or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.